Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study (vol 386, pg 1537, 2015)

被引：0
|
作者：
Roth, D.
Nelson, D. R.
Bruchfeld, A.
机构：
来源：
LANCET | 2015年 / 386卷 / 10006期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1824 / 1824
页数：1
相关论文
共 50 条
  • [1] Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study
    Roth, David
    Nelson, David R.
    Bruchfeld, Annette
    Liapakis, AnnMarie
    Silva, Marcelo
    Monsour, Howard, Jr.
    Martin, Paul
    Pol, Stanislas
    Londono, Maria-Carlota
    Hassanein, Tarek
    Zamor, Philippe J.
    Zuckerman, Eli
    Wan, Shuyan
    Jackson, Beth
    Nguyen, Bach-Yen
    Robertson, Michael
    Barr, Eliav
    Wahl, Janice
    Greaves, Wayne
    LANCET, 2015, 386 (10003): : 1537 - 1545
  • [2] C-SURFER: GRAZOPREVIR PLUS ELBASVIR IN TREATMENT-NAIVE AND TREATMENT-EXPERIENCED PATIENTS WITH HEPATITIS C VIRUS GENOTYPE 1 INFECTION AND CHRONIC KIDNEY DISEASE
    Roth, D.
    Nelson, D.
    Bruchfeld, A.
    Liapakis, A.
    Silva, M.
    Monsour, H., Jr.
    Martin, P.
    Pol, S.
    Londono, M. -C.
    Hassanein, T.
    Zamor, P.
    Zuckerman, E.
    Zhao, Y.
    Wan, S.
    Jackson, B.
    Robertson, M.
    Wahl, J.
    Barr, E.
    Greaves, W.
    JOURNAL OF HEPATOLOGY, 2015, 62 : S263 - S264
  • [3] C-SURFER: GRAZOPREVIR PLUS ELBASVIR IN TREATMENT-NAIVE AND TREATMENT-EXPERIENCED PATIENTS WITH HEPATITIS C VIRUS GENOTYPE 1 INFECTION AND CHRONIC KIDNEY DISEASE
    Bruchfeld, Annette
    Roth, David
    Nelson, David
    Liapakis, AnneMarie
    Silva, Marcelo
    Monsour, Howard
    Martin, Paul
    Pol, Stanislas
    Londono, Maria-Carlota
    Hassanein, Tarek
    Zamor, Philippe
    Zuckerman, Eli
    Zhao, Yue
    Robertson, Michael
    Wahl, Janice
    Barr, Eliav
    Greaves, Andwayne
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2015, 30
  • [4] C-SURFER: GRAZOPREVIR PLUS ELBASVIR IN TREATMENT-NAIVE AND TREATMENT-EXPERIENCED PATIENTS WITH HEPATITIS C VIRUS (HCV) GENOTYPE 1 INFECTION AND CHRONIC KIDNEY DISEASE (CKD)
    Bruchfeld, A.
    Roth, D.
    Nelson, D.
    Liapakis, A.
    Silva, M.
    Monsour, H., Jr.
    Martin, P.
    Pol, S.
    Londono, M. -C.
    Hassanein, T.
    Zamor, P.
    Zuckerman, E.
    Zhao, Y.
    Robertson, M.
    Wahl, J.
    Barr, E.
    Greaves, W.
    TRANSPLANT INTERNATIONAL, 2015, 28 : 10 - 10
  • [5] Elbasvir (EBR)/grazoprevir (GZR) treatment of hepatitis C virus (HCV) infection in patients with chronic kidney disease stage 4/5: Final results of the C-SURFER phase 3 study
    Barr, E.
    Roth, D.
    Bruchfeld, A.
    Martin, P.
    Nelson, D. R.
    Silva, M.
    Monsour, H.
    Alric, L.
    Wan, S.
    Jackson, B.
    Nguyen, B. Y.
    Wahl, J.
    Greaves, W.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2016, 31 : 65 - 66
  • [6] Cost-effectiveness of elbasvir/grazoprevir use in treatment-naive and treatment-experienced patients with hepatitis Cvirus genotype 1 infection and chronic kidney disease in the United States
    Elbasha, E.
    Greaves, W.
    Roth, D.
    Nwankwo, C.
    JOURNAL OF VIRAL HEPATITIS, 2017, 24 (04) : 268 - 279
  • [7] ELBASVIR/GRAZOPREVIR PLUS SOFOSBUVIR IN TREATMENT-NAIVE AND TREATMENT-EXPERIENCED CIRRHOTIC PATIENTS WITH HEPATITIS C VIRUS GENOTYPE 3 INFECTION TREATED FOR 8, 12 OR 16 WEEKS: FINAL RESULTS OF THE C-ISLE STUDY
    Haber, Barbara
    Foster, Graham R.
    Agarwal, Kosh
    Cramp, Matthew E.
    Moreea, Sulleman
    Barclay, Stephen
    Collier, Jane
    Brown, Ashley S.
    Ryder, Stephen D.
    Ustianowski, Andrew
    Forton, Daniel
    Fox, Raymond
    Gordon, Fiona
    Rosenberg, William
    Mutimer, David J.
    Du, Jiejun
    Gilbert, Christopher L.
    Robertson, Michael
    Barr, Eliav
    GASTROENTEROLOGY, 2017, 152 (05) : S1061 - S1061
  • [8] Grazoprevir plus elbasvir and other treatment options in hepatitis C infected patients with stage 4-5 chronic kidney disease
    Bhamidimarri, Kalyan Ram
    ANNALS OF TRANSLATIONAL MEDICINE, 2016, 4
  • [9] Elbasvir/grazoprevir plus sofosbuvir in treatment-naive and treatment-experienced cirrhotic patients with hepatitis C virus genotype 3 infection treated for 8, 12, or 16 weeks: final results of the C-ISLE study
    Foster, G. R.
    Agarwal, K.
    Cramp, M. E.
    Moreea, S.
    Barclay, S.
    Collier, J.
    Brown, A. S.
    Ryder, S. D.
    Ustianowski, A.
    Forton, D. M.
    Fox, R.
    Gordon, F.
    Rosenberg, W. M.
    Mutimer, D. J.
    Du, J.
    Gilbert, C. L.
    Robertson, M.
    Barr, E.
    Haber, B.
    JOURNAL OF HEPATOLOGY, 2017, 66 (01) : S503 - S504
  • [10] Elbasvir/Grazoprevir (EBR/GZR) treatment of Hepatitis C Virus (HCV) infection in patients with chronic kidney disease (CKD) stage 4/5: clinical, virological, and health-related quality of life outcomes in the C-SURFER study
    Bruchfeld, Annette
    Roth, David
    Martin, Paul
    Nelson, David
    Stanislas, Pol
    Carlota Londono, Maria
    Viviani, Daniele
    Wan, Shyan
    Arduino, Jeanmarie
    Robertson, Michael
    Nguyen, Bachyen
    Wahl, Janice
    Barr, Eliav
    Greaves, Wayne
    SWISS MEDICAL WEEKLY, 2016, 146 : 23S - 23S
12345